Clinical trials: Severe Asthma
Moderate to Severe Asthma
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous [SC] every 4 weeks [Q4W]) on antibody responses…
- Trial name
- VECTOR (NCT05062759)
- Testing
- Tezepelumab
- Where
- 15 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Asthma
A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
The purpose of this study is to determine whether the addition of tralokinumab to standard asthma medication is effective in the treatment of adults with asthma.
- Trial name
- NCT01402986
- Testing
- Tralokinumab 300 mg, Q2W, Tralokinumab 300 mg, Q2/4W
- Where
- 89 sites in United States, Argentina and 13 more
- Volunteers
- 689 people
- Sponsor
- MedImmune LLC
Asthma
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium…
- Trial name
- ARGON (NCT03158311)
- Testing
- QVM149, Salmeterol/fluticasone plus tiotropium
- Where
- 163 sites in Argentina, Chile and 18 more
- Volunteers
- 1,426 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications
The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate (50, 100, 200, and 400mcg) delivered as Fluticasone Spiromax® Inhalation Powder (Fp…
- Trial name
- NCT01576718
- Testing
- Fp MDPI, Flovent Diskus, albuterol/salbutamol
- Where
- 300 sites in United States, Australia and 17 more
- Volunteers
- 889 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily [od]), compared with salmeterol (50 μg twice a day [b.i.d.]), over 26 weeks, in patients with moderate to severe…
- Trial name
- NCT00529529
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 126 sites in United States, Argentina and 10 more
- Volunteers
- 805 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home
The purpose of the study is to assess functionality, performance, and reliability of an single-use auto-injector (AI) with benralizumab administered subcutaneously (SC) in an at-home setting reported by the patient or caregiver…
- Trial name
- GRECO (NCT02918071)
- Testing
- Benralizumab
- Where
- 25 sites in United States, Canada
- Volunteers
- 121 people
- Sponsor
- AstraZeneca
Persistent Allergic Asthma
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite…
- Trial name
- NCT01202903
- Testing
- Omalizumab
- Where
- 39 sites in China
- Volunteers
- 616 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
The purpose of this study is to determine the efficacy and safety of multiple CSJ117 doses (0.5; 1; 2; 4 and 8 mg) inhaled once daily compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult patients…
- Trial name
- NCT04410523
- Testing
- CSJ117
- Where
- 113 sites in United States, Argentina and 13 more
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma
The purpose of this study is to evaluate the safety and tolerability of MN-221 at two different dosing rates administered through a continuous infusion in subjects diagnosed with moderate to severe asthma.
- Trial name
- NCT00679263
- Testing
- MN-221
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- MediciNova
Severe Asthma
Impulse Oscillometry Measurements in Severe Eosinophilic Asthmatics Before and After Anti-IL-5 Factor Initiation
Eosinophilic inflammation in the small airways of patients with severe asthma is considered to be an important marker of disease severity.
- Trial name
- IMPOSE (NCT05147155)
- Testing
- Mepolizumab
- Where
- Greece
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Thessaly
Asthma
Study to Evaluate the Safety and Efficacy of CAT-354
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel-arm study to evaluate the efficacy and safety of 3 subcutaneous (SC) treatment regimens of CAT-354 in adult subjects with uncontrolled…
- Trial name
- NCT00873860
- Testing
- CAT-354 150 mg, CAT-354 300 mg, CAT-354 600 mg
- Where
- 57 sites in Bulgaria, Germany and 3 more
- Volunteers
- 357 people
- Sponsor
- MedImmune LLC
Asthma
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially controlled on medium or high doses of inhaled…
- Trial name
- NCT05935332
- Testing
- RPT193
- Where
- 29 sites in United States, Bulgaria and 2 more
- Volunteers
- 38 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Asthma
Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
This is a multi-center, randomized, placebo-controlled, double-blind, parallel group study that aims to assess the efficacy and safety of GSK3511294 (Depemokimab) in participants with severe uncontrolled asthma with an…
- Trial name
- SWIFT-1 (NCT04719832)
- Testing
- GSK3511294 (Depemokimab)
- Where
- 123 sites in United States, Canada and 10 more
- Volunteers
- 395 people
- Sponsor
- GlaxoSmithKline
Asthma
Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
Subjects who completed either D5180C00007 or D5180C00009 will be offered the opportunity to consent for the Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate…
- Trial name
- DESTINATION (NCT03706079)
- Testing
- Tezepelumab
- Where
- 180 sites in United States, Argentina and 16 more
- Volunteers
- 951 people
- Sponsor
- AstraZeneca
Allergic Rhinitis, Asthma
An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma
The primary objective of this study is to explore the efficacy of Nasonex (mometasone furoate nasal spray) in comparison with placebo in improving the quality of life of subjects with moderate to severe persistent allergic…
- Trial name
- NCT00599027
- Testing
- Mometasone furoate nasal spray (MFNS)
- Volunteers
- 51 people
- Sponsor
- Organon and Co
Asthma
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in…
- Trial name
- NCT03299686
- Testing
- CJM112
- Where
- 29 sites in United States, Argentina and 6 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
This was a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment.
- Trial name
- TIDE-asthma (NCT05421598)
- Testing
- Amlitelimab
- Where
- 113 sites in United States, Argentina and 12 more
- Volunteers
- 437 people
- Sponsor
- Sanofi
Asthma Exacerbation
Effectiveness of the Aeroneb in Acute Severe Asthma
Background: The bronchodilator therapy is an essential component of the management of asthma exacerbation. The delivery of bronchodilators to the lungs in asthma exacerbations is usually achieved through nebulization (creating…
- Trial name
- NCT03029156
- Testing
- Aeroneb nebulizer, Small volume jet nebulizer
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Tufts Medical Center
Asthma
Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation
The purpose of this study is to evaluate the effectiveness of nebulized magnesium sulfate as a vehicle for albuterol in children with moderate to severe asthma exacerbation.
- Trial name
- NCT01515995
- Testing
- Nebulized magnesium sulfate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals